De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Standard Chemical & Pharmaceutical Beheer

Beheer criteriumcontroles 0/4

De CEO Standard Chemical & Pharmaceutical's is Tzu-Ting Fan, benoemd in Jul2008, heeft een ambtstermijn van 16.25 jaar. bezit rechtstreeks 6.58% van de aandelen van het bedrijf, ter waarde NT$ 757.77M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.6 jaar en 0.8 jaar.

Belangrijke informatie

Tzu-Ting Fan

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	16.3yrs
Eigendom CEO	6.6%
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Standard Chemical & Pharmaceutical (TWSE:1720) Is Increasing Its Dividend To NT$2.70

Jul 29

Standard Chemical & Pharmaceutical (TWSE:1720) Will Pay A Larger Dividend Than Last Year At NT$2.70

Jul 14

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

Apr 13

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Jan 19

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Jan 04

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

Dec 22

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Dec 08

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Nov 26

CEO

Tzu-Ting Fan

16.3yrs

Tenure

Mr. Tzu-Ting Fan serves as Chairman of the Board since June 28, 2024 and serves as its General Manager Standard Chem. & Pharm. Co., Ltd.and its President since July 1, 2008. He served as Director at Stand...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Tzu-Ting Fan	Chairman of the Board	16.3yrs	geen gegevens	6.58% NT$ 757.8m
Chin Wen Chang	Financial Officer	1.6yrs	geen gegevens	geen gegevens
Chin-Tsai Fan	GM & Director	1.6yrs	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van 1720 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Tzu-Ting Fan	Chairman of the Board	less than a year	geen gegevens	6.58% NT$ 757.8m
Chin-Tsai Fan	GM & Director	less than a year	geen gegevens	geen gegevens
Yuan-Teh Lee	Director	no data	geen gegevens	geen gegevens
Wen-Chang Lin	Director	less than a year	geen gegevens	0.052% NT$ 6.0m
Hwei-Jiung Wang	Independent Director	no data	geen gegevens	geen gegevens
Tsuey-Wen Yeh	Director	3.8yrs	geen gegevens	geen gegevens
Shaw-Tzong Liu	Independent Director	3.2yrs	geen gegevens	geen gegevens
Lawrence C. Lee	Additional Independent Director	1.3yrs	geen gegevens	geen gegevens
Yi-Zhen Zhang	Independent Director	less than a year	geen gegevens	geen gegevens
Shao-Zong Liu	Independent Director	less than a year	geen gegevens	geen gegevens
Yi-Chen Chang	Independent Director	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 1720 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.

Standard Chemical & Pharmaceutical Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, Jun 20, 2024

Standard Chemical & Pharmaceutical Co. Ltd. Elects One Additional Director and One Additional Independent Director

Less than half of directors are independent

Less than half of directors are independent

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 21, 2022

Recent updates

Second quarter 2024 earnings released: EPS: NT$1.21 (vs NT$1.33 in 2Q 2023)

Standard Chemical & Pharmaceutical Co. Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Standard Chemical & Pharmaceutical (TWSE:1720) Is Increasing Its Dividend To NT$2.70

Upcoming dividend of NT$2.70 per share

Standard Chemical & Pharmaceutical (TWSE:1720) Will Pay A Larger Dividend Than Last Year At NT$2.70

Dividend of NT$2.70 announced

High number of new directors

First quarter 2024 earnings released: EPS: NT$1.41 (vs NT$1.18 in 1Q 2023)

Standard Chemical & Pharmaceutical Co. Ltd. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings released: EPS: NT$4.67 (vs NT$4.56 in FY 2022)

Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, Jun 20, 2024

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2023 earnings released: EPS: NT$1.25 (vs NT$1.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$1.33 (vs NT$1.28 in 2Q 2022)

Upcoming dividend of NT$2.50 per share at 3.8% yield

Standard Chemical & Pharmaceutical Co. Ltd. Elects One Additional Director and One Additional Independent Director

Investor sentiment improves as stock rises 22%

Full year 2022 earnings released: EPS: NT$4.56 (vs NT$3.96 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$1.34 (vs NT$0.89 in 3Q 2021)

Now 20% undervalued

Now 20% undervalued

Second quarter 2022 earnings released: EPS: NT$1.28 (vs NT$0.93 in 2Q 2021)

Upcoming dividend of NT$2.50 per share

First quarter 2022 earnings released: EPS: NT$0.97 (vs NT$1.17 in 1Q 2021)

Less than half of directors are independent

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS NT$0.89 (vs NT$0.64 in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.73 in 2Q 2020)

Upcoming dividend of NT$1.80 per share

First quarter 2021 earnings released: EPS NT$1.17 (vs NT$0.67 in 1Q 2020)

If You Like EPS Growth Then Check Out Standard Chem & Pharm (TPE:1720) Before It's Too Late

SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777) agreed to acquire API synthesis department of Standard Chemical from Standard Chem & Pharm CO., LTD. (TSEC:1720) for TWD 341 million.

Full year 2020 earnings released: EPS NT$2.93 (vs NT$2.11 in FY 2019)

Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 18, 2021

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Does Standard Chem & Pharm (TPE:1720) Have A Healthy Balance Sheet?

Should Standard Chem & Pharm (TPE:1720) Be Disappointed With Their 11% Profit?

Is Standard Chem & Pharm CO., LTD.'s (TPE:1720) 4.3% Dividend Worth Your Time?

New 90-day low: NT$35.20

Standard Chem & Pharm CO., LTD.'s (TPE:1720) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

New 90-day low: NT$36.50

Here's Why I Think Standard Chem & Pharm (TPE:1720) Might Deserve Your Attention Today

Is Standard Chem & Pharm CO., LTD. (TPE:1720) Popular Amongst Insiders?

A Look At The Fair Value Of Standard Chem & Pharm CO., LTD. (TPE:1720)

Standard Chem & Pharm (TPE:1720) Seems To Use Debt Rather Sparingly

Third quarter 2020 earnings released: EPS NT$0.64

New 90-day low: NT$37.55

New 90-day low: NT$37.70

New 90-day low - NT$38.30

First half earnings released

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur